For patient 1 (BCR-ABL+), no CD19-TRAIL-treated animal showed clinical signs of leukemia up to day +160, whereas all control animals were sacrificed due to overt leukemia on day +80 (p = 0.0035). This evidence concerns the gene ABL1 and leukemia.